AssetMark’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$291 Sell
30
-268
-90% -$3.1K ﹤0.01% 3547
2026
Q2
$3.47K Sell
298
-510
-63% -$7.28K ﹤0.01% 2810
2026
Q1
$13.6K Sell
808
-26
-3% -$465 ﹤0.01% 2204
2025
Q4
$13.4K Sell
834
-397
-32% -$5.91K ﹤0.01% 2125
2025
Q3
$15.2K Sell
1,231
-6,299
-84% -$73.8K ﹤0.01% 2000
2025
Q2
$86.7K Buy
7,530
+4,643
+161% +$55.1K ﹤0.01% 1403
2025
Q1
$43.3K Buy
2,887
+1,387
+92% +$23.2K ﹤0.01% 1477
2024
Q4
$26K Buy
+1,500
New +$28.9K ﹤0.01% 1593
2022
Q2
– Sell
-3
Closed – – 1494
2022
Q1
$0 Buy
+3
New +$84 ﹤0.01% 1571
2020
Q1
– Sell
-32
Closed -$1K – 1377
2019
Q4
$1K Hold
32
– – ﹤0.01% 1297
2019
Q3
$1K Hold
32
– – ﹤0.01% 1224
2019
Q2
$2K Hold
32
– – ﹤0.01% 1146
2019
Q1
$2K Sell
32
-8
-20% -$536 ﹤0.01% 1156
2018
Q4
$2K Hold
40
– – ﹤0.01% 1204
2018
Q3
$5K Sell
40
-2
-5% -$226 ﹤0.01% 1162
2018
Q2
$5K Sell
42
-116
-73% -$14.1K ﹤0.01% 1156
2018
Q1
$17K Sell
158
-91
-37% -$10.1K ﹤0.01% 961
2017
Q4
$27K Sell
249
-209
-46% -$20.9K ﹤0.01% 945
2017
Q3
$45K Buy
458
+52
+13% +$5.04K ﹤0.01% 726
2017
Q2
$41K Buy
406
+25
+7% +$2.7K ﹤0.01% 727
2017
Q1
$44K Hold
381
– – ﹤0.01% 669
2016
Q4
$46K Hold
381
– – ﹤0.01% 640
2016
Q3
$43K Sell
381
-164
-30% -$18.9K ﹤0.01% 649
2016
Q2
$68K Buy
545
+330
+153% +$39.8K ﹤0.01% 542
2016
Q1
$24K Buy
215
+159
+284% +$16.5K ﹤0.01% 725
2015
Q4
$6K Buy
56
+37
+195% +$4.24K ﹤0.01% 944
2015
Q3
$2K Buy
+19
New +$2.07K ﹤0.01% 630

Other funds holding CLB

AssetMark's CLB Position: Q3 2026 in Review

AssetMark reduced its Core Laboratories (CLB) stake by 90% in Q3 2026, selling an estimated $3.1K and leaving 30 shares worth $291. The position accounts for ﹤0.01% of the portfolio, ranked #3547.

AssetMark first reported a position in CLB in Q3 2015 and has held it in 27 quarters since. The position peaked at $86.7K in Q2 2025. 131 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • AssetMark held 30 shares of Core Laboratories worth $291 as of Q3 2026.
  • AssetMark sold 268 Core Laboratories shares in Q3 2026, an estimated $3.1K.
  • Core Laboratories made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3547 holding.
  • AssetMark first reported a position in Core Laboratories in Q3 2015 and has held it in 27 quarters since.
  • AssetMark's Core Laboratories position peaked at $86.7K in Q2 2025.
  • 131 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.